340B Discounts Linked To Lower Hospital Costs For COPD When Savings Pass Directly To Patients
Executive Summary
Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.